IntelliPharmaCeutics International Inc. (IPCI) Analysts See $-0.05 EPS

March 19, 2018 - By Dolores Ford

 IntelliPharmaCeutics International Inc. (IPCI) Analysts See $ 0.05 EPS

Analysts expect IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) to report $-0.05 EPS on April, 10.They anticipate $0.02 EPS change or 28.57 % from last quarter’s $-0.07 EPS. After having $-0.08 EPS previously, IntelliPharmaCeutics International Inc.’s analysts see -37.50 % EPS growth. The stock decreased 3.11% or $0.0199 during the last trading session, reaching $0.6201. About 10,074 shares traded. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has risen 16.57% since March 19, 2017 and is uptrending. It has underperformed by 0.13% the S&P500.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering Intellipharmaceutics Intl (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Intellipharmaceutics Intl had 8 analyst reports since December 31, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group on Tuesday, June 6 with “Buy”. As per Thursday, December 31, the company rating was maintained by Maxim Group. The firm has “Hold” rating by Maxim Group given on Friday, February 16. Maxim Group maintained the shares of IPCI in report on Friday, June 30 with “Buy” rating. H.C. Wainwright maintained IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) on Monday, February 12 with “Buy” rating. The firm has “Buy” rating by Maxim Group given on Friday, July 21. The firm earned “Buy” rating on Monday, March 5 by H.C. Wainwright.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $25.04 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

More notable recent IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news were published by: which released: “Intellipharmaceutics International Inc.” on July 27, 2017, also with their article: “Intellipharmaceutics Reports on Launch of Additional Strengths of Generic …” published on November 30, 2017, published: “Intellipharmaceutics Announces Closing of US$4 Million Financing” on October 13, 2017. More interesting news about IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) were released by: and their article: “Intellipharmaceutics Announces Closing of US$3.5 Million Financing” published on March 16, 2018 as well as‘s news article titled: “Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista …” with publication date: April 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.